The stock of Sana Biotechnology Inc. (NASDAQ:SANA) last traded at $6.48, down -8.60% from the previous session.
Data from the available sources indicates that Sana Biotechnology Inc. (NASDAQ:SANA) is covered by 5 analysts. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $13.00 and a low of $6.00, we find $8.50. Given the previous closing price of $7.09, this indicates a potential upside of 19.89 percent. SANA stock price is now 33.27% away from the 50-day moving average and 26.58% away from the 200-day moving average. The market capitalization of the company currently stands at $1.26B.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
Sponsored
In total, 3 analysts have assigned it a hold rating, and 2 have given it a buy rating. Brokers who have rated the stock have averaged $9.00 as their price target over the next twelve months.
.
A total of 3.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in SANA stock. A new stake in Sana Biotechnology Inc. shares was purchased by SUVRETTA CAPITAL MANAGEMENT, LLC during the first quarter worth $13,697,000. BAKER BROS. ADVISORS LP invested $12,960,000 in shares of SANA during the first quarter. In the first quarter, JACOBS LEVY EQUITY MANAGEMENT, INC acquired a new stake in Sana Biotechnology Inc. valued at approximately $1,847,000. VERITION FUND MANAGEMENT LLC acquired a new stake in SANA for approximately $1,076,000. NEW YORK LIFE INVESTMENT MANAGEMENT LLC purchased a new stake in SANA valued at around $936,000 in the second quarter. In total, there are 197 active investors with 91.20% ownership of the company’s stock.
With an opening price of $7.01 on Wednesday morning, Sana Biotechnology Inc. (NASDAQ: SANA) set off the trading day. During the past 12 months, Sana Biotechnology Inc. has had a low of $2.99 and a high of $9.55. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 3.60, and a quick ratio of 3.60. The fifty day moving average price for SANA is $4.92 and a two-hundred day moving average price translates $5.11 for the stock.
The latest earnings results from Sana Biotechnology Inc. (NASDAQ: SANA) was released for Mar, 2023.
Sana Biotechnology Inc.(SANA) Company Profile
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG299 and SG242 that targets CD19+ cancer cells in patients with non-Hodgkin Lymphoma (NHL), chronic lymphocytic leukemia (CLL), and acute lymphoblastic leukemia (ALL); SG221 and SG239 for the treatment of multiple myeloma; and SG233, a CD22 CAR for the treatment of NHL, CLL, and ALL. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255, a B cell maturation antigen directed allogeneic CAR T for multiple myeloma; SC45, the PSC-derived pancreatic islet cells for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, Huntington’s disease, and other astrocytic diseases. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is based in Seattle, Washington.
